Mayo Clinic Finds Way to Stop Ovarian Cancer Resistance

Scientists at Mayo Clinic just figured out why ovarian cancer treatments stop working, and they found a way to fix it using a drug that's already FDA-approved.

For years, doctors have watched ovarian cancer patients respond well to PARP inhibitors at first, only to see the tumors grow back months later. Everyone assumed resistance developed slowly over time, but this new research reveals something surprising: cancer cells flip their survival switch within hours of the first dose.

Dr. Arun Kanakkanthara and his team discovered that a protein called FRA1 acts like an emergency alarm in ovarian cancer cells. The moment PARP inhibitors arrive, FRA1 turns on genes that help the cancer adapt and escape death. It's like the tumor has a backup generator that kicks in the second the power goes out.

The team tested whether brigatinib, a drug currently used for lung cancer, could shut down this early survival response. The results were remarkable: combining brigatinib with PARP inhibitors worked far better than either drug alone. Even better, the combination targeted cancer cells while leaving healthy cells unharmed.

The research revealed something unexpected about how brigatinib works. Instead of affecting DNA repair like most cancer drugs, it blocks two specific signaling pathways that aggressive tumors depend on: FAK and EPHA2. Hitting both targets at once makes it much harder for cancer cells to adapt and survive.

The Ripple Effect

This discovery could change how doctors approach ovarian cancer from day one. Dr. John Weroha, a medical oncologist at Mayo Clinic, sees potential to prevent resistance before it ever takes hold. Starting patients on the drug combination early could mean longer remissions and better outcomes.

The research also offers a way to identify which patients would benefit most. Tumors with high levels of FAK and EPHA2 responded strongest to the combination therapy. Since these same markers show up in the most aggressive cancers, the treatment could be especially powerful for the hardest cases.

Because brigatinib is already approved by the FDA, it could move to clinical trials much faster than a brand new drug. That means women with ovarian cancer might see this option available sooner rather than later.

The findings give hope to the 20,000 American women diagnosed with ovarian cancer each year, many of whom face the heartbreak of treatments that eventually stop working.